A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

NCT05286619 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

University of Malaya

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]